BioSpace News Archive

Humacyte, Inc. announced an oral presentation on the Company’s Human Acellular Vessel by Todd E. Rasmussen, M.D., FACS, at the 44th International Committee on Military Medicine World Congress was given on September 7, 2022.

Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announces that the last patient of the 103 enrolled subjects since April 2021 has completed their 24-week study visit in the Phase 2b ZETA-1 trial of oral APX3330 for the treatment of diabetic retinopathy (DR).

Portage Biotech Inc. announced that the Company’s management team will be presenting at the following upcoming investor conferences.

Hummingbird Bioscience today announced that Johann de Bono, Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, will present a trial in progress poster outlining the Phase 1 clinical trial design for HMBD-001 at the European Society for Medical Oncology Congress (ESMO 2022).

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2022 list in the large company category.

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in notalgia paresthetica (NP).

ReWalk Robotics Ltd., a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022.

PolarityTE, Inc. announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.

Medivir AB announces that an abstract about its lead program fostroxacitabine bralpamide and the potential efficacy in primary liver cancer has been accepted for presentation at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, USA.